PAVmed Inc (PAVM) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of PAVmed Inc stock $2.26, price $1.75, upside +29.2%, quality 17 out of 100. Rating: undervalued. Calculated from audited financials with 11 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
PAVmed Inc
PAVM · USCheap (23% below fair value), but weak company and price moving sideways: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $1.34 – $3,642 · fair‑value band $2.18 – $2.44 · the $1.75 price screens below the $2.26 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether PAVmed is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States.
Show moreShow less
The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device.
Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015.
PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Stock analysis
PAVmed Inc (PAVM) currently trades at $1.75, while our model-based Fair Value estimate is $2.26, implying the stock looks roughly 23% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $9.64 per share, and 8 of the 11 models we run sit above the $1.75 price.
Bear case: the Asset-Based group reads lowest at $0.9000, and 3 of the 11 models stay below the price. Data coverage for this calculation is low.
Scenario range: $2.18 (bear) to $2.44 (bull), the price of $1.75 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 17/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
PAVmed Inc reported revenue of $71.0K in FY2025 versus $500K in FY2021, a compound −38.6%/yr. Reported net income was $401K in FY2025.
Key figures
Market cap $13.0M Micro · EPS (TTM) $−14.20 · Return on equity −64.8% · Return on assets (EBIT) −128% (5-year average) · Operating margin −23,842% · Revenue (TTM) $112K · Revenue growth (YoY) +450% · Free cash flow −$5.2B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (low confidence).
What moves the price
The share trades about 85% below its 52-week high and 31% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at −16% fair-value upside, at 29%, PAVM screens cheaper than that median.
Fair Value models
All 11 models by family
The fair value above starts from this blend and is adjusted for dilution from new shares.
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Watch PAVM, get fair value alerts →
Compare PAVmed Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 401 stocks
Valuation Multiplesvs Medical Devices median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- EBIT margin by industry
- P/S ratio by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| DexCom, Inc DXCM | $81.61 | $91.66 | +12% | vs PAVM |
| Boston Scientific Corporation BSX | $43.69 | $48.77 | +12% | vs PAVM |
| Stryker Corporation SYK | $310.72 | $340.60 | +10% | vs PAVM |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥184.30 | ¥197.34 | +7% | vs PAVM |
| GE HealthCare Technologies Inc GEHC | $82.96 | $69.92 | −16% | vs PAVM |
| Siemens Healthineers AG SHL | €44.00 | €34.51 | −22% | vs PAVM |
| Edwards Lifesciences Corporation EW | $107.11 | $81.94 | −24% | vs PAVM |
| Medtronic plc MDT | $102.88 | $74.89 | −27% | vs PAVM |
| Abbott Laboratories, ABT | $107.45 | $75.28 | −30% | vs PAVM |
| Koninklijke Philips N.V PHIA | €27.54 | €15.23 | −45% | vs PAVM |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is PAVmed Inc (PAVM) overvalued or undervalued?
What is the fair value of PAVM?
What is the quality score of PAVM?
What is the price target for PAVmed Inc (PAVM)?
What is the PAVmed Inc stock forecast for 2026?
What is the revenue of PAVmed Inc (PAVM)?
What is the intrinsic value of PAVmed Inc (PAVM)?
Is PAVmed Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of PAVM?
How much is PAVmed Inc worth?
What do the bullish and bearish scenarios say about PAVM?
How solid is the balance sheet of PAVmed Inc (PAVM)?
How far is PAVM from its 52-week high?
Which stocks are comparable to PAVmed Inc?
Is PAVmed Inc stock attractive at the current price?
How is the fair value of PAVM calculated?
Is it still worth investing in stocks now?
What is the share price of PAVmed Inc (PAVM)?
What should I pay attention to with PAVmed Inc right now?
Key figures of PAVmed Inc
How large is the market capitalisation of PAVmed Inc (PAVM)?
What are the earnings per share of PAVmed Inc (PAVM)?
What is the return on equity of PAVmed Inc (PAVM)?
What is the EBIT return on assets of PAVmed Inc (PAVM)?
What is the operating margin of PAVmed Inc (PAVM)?
How fast is revenue growing at PAVmed Inc (PAVM)?
How much free cash flow does PAVmed Inc (PAVM) generate?
How much net debt does PAVmed Inc (PAVM) carry?
Why does PAVmed Inc meet the fair value rule although the fair value shown is lower?
Watch PAVmed Inc in the live analysis
One click puts PAVmed Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.